US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Elicera Therapeutics presents first clinical results from iTANK-armed CAR T-cell therapy at scientific conference

Gothenburg, January 21, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, announces today that the first patient in the CAR T-cell study CARMA, which evaluates the efficacy of ELC-301 against B-cell lymphoma, has been successfully treated. The one-month follow-up after treatment shows that the patient achieved a complete response with only very mild side effects. The treatment outcome will now be presented at the Cancer Crosslinks conference in Oslo

BioStock: Elicera’s candidate ELC-100 granted Orphan Drug Designation

Cell and gene therapy company Elicera Therapeutics has been granted Orphan Drug Designation (ODD) by the FDA for its drug candidate ELC-100, intended for the treatment of pancreatic neuroendocrine tumors. This highlights the potential of the oncolytic virus as a promising therapy for this challenging type of cancer.Read the article at biostock.se: Elicera’s candidate ELC-100 granted Orphan Drug Designation  This is a press release from BioStock - Connecting Innovation & Capital. https://www.

Elicera Therapeutics' drug candidate ELC-100 receives Orphan Drug Designation in the U.S. for the treatment of pancreatic neuroendocrine tumors

Gothenburg, January 13, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, announces today that the company's drug candidate ELC-100 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic neuroendocrine tumors. This designation provides benefits during the continued development of the drug candidate and in the event of potential marketing approval of the treatment.Orphan Drug

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2024

Third quarter (July-September 2024) · Operating profit/loss amounted to SEK -2,697,267 (-5,149,440). · Loss for the period amounted to SEK -2,514,629 (-5,046,574). · Cash flow from operating activities totalled SEK -2,233,409 (-2,243,671). · Earnings per share before and after dilution totalled SEK – 0.07 (-0.26).   Period (January-September 2024) · Operating profit/loss amounted to SEK -13,972,098 (-11,881,583). · Loss for the period amounted to SEK -13 507,085 (-11,648,755). · Cash flow from operating activities totalled SEK -19,231,075 (-18,425,660). ·

BioStock: Elicera’s CEO: “ELC-100 stands apart from all other standard treatments”

Elicera Therapeutics is well-established in the field of cell and gene therapy. Just over a month ago, the company completed patient recruitment for its phase I/II study with ELC-100. Results from the first part of the study are expected in H1 2025. BioStock spoke with CEO Jamal el-Mosleh to hear his thoughts on this achievement.Read the interview at biostock.se: https://www.biostock.se/en/2024/11/eliceras-ceo-elc-100-stands-apart-from-all-other-standard-treatments/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock: Elicera’s CEO: “One of the biggest milestones in our history”

Elicera Therapeutics has officially entered clinical trials with its drug candidate ELC-301. This CAR T-cell therapy is being evaluated in a phase I/IIa study on patients with hard-to-treat B-cell lymphomas, mantle cell lymphoma, or indolent lymphomas where standard treatments have failed. By launching the CARMA study, Elicera takes a significant step forward, advancing cancer treatment and positioning itself as a pioneer in Swedish CAR T-cell research.Read the interview at biostock.se: https://www.biostock.se/en/2024/11/eliceras-ceo-one-of-the-biggest-milestones-in-our-history/ This

Elicera Therapeutics includes the first patient in the Phase I/II clinical study CARMA targeting B-cell lymphoma

Gothenburg, November 5, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, announced today that the first patient has been enrolled in the company's Phase I/II clinical study, CARMA. The study aims to evaluate the iTANK-armed CAR T-cell therapy, ELC-301, in patients with hard-to-treat B-cell lymphoma, mantle cell lymphoma, or indolent lymphoma who have not responded to standard treatment or have experienced a relapse of the disease.The study will be

Elicera Therapeutics will present at the BioStock Life Science Summit, November 20

The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CEO Jamal El-Mosleh will present Elicera Therapeutics to industry leaders, specialist investors and potential partners.The Summit connects innovation and capital, providing small-to-medium size Nordic companies from a wide range of therapeutic areas the platform and opportunity to make their case to both Swedish and international investors as well as top-level potential partners in a unique boutique setting.    Date: November 20 Time: 14:30 Location: Auditorium at Medicon Village,

Elicera Therapeutics enrolls the last patient in the clinical phase I/II-trial with oncolytic virus ELC-100

Gothenburg, October 24, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on CAR T-cell therapies and oncolytic viruses, armed with its proprietary commercially available technology platform iTANK, announced today that the last patient has been enrolled in the clinical phase I/II study evaluating the company's oncolytic drug candidate ELC-100 (AdVince) against neuroendocrine tumors. The study's preliminary results are expected to be reported in the first half of 2025.The study, which is sponsored by

Elicera Therapeutics will participate in upcoming industry and investor conferences during the fall

Gothenburg, September 3, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on CAR T-cell therapies and oncolytic viruses, armed with its proprietary and commercially available technology platform iTANK, announces that the company will participate in the following industry and investor conferences during the fall of 2024:ISCT Europe 2024 Regional Meeting, September 4 Elicera Therapeutics will participate in the annual conference organized by the scientific network International Society for Gene & Cell

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2024

Second quarter (April-June 2024) · Operating profit/loss amounted to SEK -5,841,409 (-4 466 286). · Loss for the period amounted to SEK -5,622,779 (-4,335,852). · Cash flow from operating activities totalled SEK -7,733,270 (-2,146,178). · Earnings per share before and after dilution totalled SEK -0.16 (-0,22). Period (January-June 2024) · Operating profit/loss amounted to SEK -11,274,831 (-6,372,143). · Loss for the period amounted to SEK -10,992,456 (-6,602,181). · Cash flow from operating activities totalled SEK -16,997,666 (-4,181,989). · Earnings per share

BioStock: Elicera teams up with China Medical University for cancer study

Elicera Therapeutics has announced a new research collaboration with the Fourth Affiliated Hospital of China Medical University to assess the efficacy of oncolytic virus ELC-201 in preclinical proof-of-concept studies. This collaboration will explore the potential of ELC-201 across various solid tumour indications. BioStock turned to Elicera’s CEO Jamal El-Mosleh to learn more.Read the article at biostock.se: Elicera teams up with China Medical University for cancer study - BioStock 

Elicera Therapeutics enters a preclinical collaboration agreement with China Medical University for the development of ELC-201

Gothenburg, June 11, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on CAR T-cell therapies and oncolytic viruses, armed with its proprietary commercially available technology platform iTANK, announces today that the company has entered a research collaboration with Fourth Affiliated Hospital of China Medical University (CMU4). Through this agreement, the efficacy of the oncolytic virus ELC-201 will be evaluated in preclinical proof-of-concept studies across multiple solid tumor indications.According

BioStock: Elicera’s first clinical CAR T-Cell study CARMA set to begin

Elicera Therapeutics is on the brink of launching its first clinical CAR T-cell study, CARMA, which aims to generate crucial data for its lead CAR T-cell candidate ELC-301 and the iTANK immune-boosting technology.– We expect to be able to treat the first patients after summer and thus present interim data from the first dosage group with three patients at the turn of the year 2024/2025, says CEO Jamal El-Mosleh in Elicera’s 2024 Q1 report.Read the article at biostock.se: https://www.biostock.se/en/2024/05/eliceras-first-clinical-car-t-cell-study-carma-set-to-begin/ This is a press

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2024

First quarter (January-March 2024) · Operating profit/loss amounted to SEK - 5,433,422 (-2,265,857). · Loss for the period amounted to SEK - 5,369,677 (-2,266,329). · Cash flow from operating activities totaled SEK -9,264,396 (-2,035,828). · Earnings per share before dilution totaled SEK – 0.26 (-0,11) ). Earnings per share after dilution totaled SEK -0.26 (-0.11).   Key events during the first quarter · Elicera participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand.

Elicera Therapeutics publishes the annual report for 2023

Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties, using the company’s proprietary and commercially available platform iTANK, publishes the annual report for 2023.   Elicera Therapeutics annual report is now available at the webpage https://www.elicera.com.   The Annual General Meeting will be held on May 16th at 1:00 p.m. at the offices of Advokatfirman Delphi (Mäster Samuelsgatan 17 in Stockholm).

Nomination committee proposes CMC specialist to Elicera’s board of directors

The Nomination Committee of Elicera Therapeutics AB (publ) proposes Sharon Longhurst as new board member. Sharon Longhurst is a specialist in CMC (Chemistry, Manufacturing and Control) and has solid experience for the development that is planned in Elicera.   Elicera informed in a press release on October 31, 2023 that a Nomination Committee was formed ahead of the annual meeting on May 16, 2024.   The Nomination Committee consists of Magnus Essand (chair), Di Yu and Jamal El-Mosleh, that together controlled 47.1 of the votes. The Nomination Committee has thus unanimously

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Mangold Fondkommission AB

Elicera has entered into agreements with Mangold regarding the position as Certified Adviser and Liquidity provider. Mangold will take over as Certified Adviser and Liquidity provider on May 15, 2024. Until then, Carnegie will continue to act as Certified Adviser and Liquidity provider to the Company. Elicera is consequently increasing the cooperation with Mangold , that recently has acted as financial advisor for the recently completed new issue.       For further information please contact: Jamal El-Mosleh, CEO, Elicera Therapeutics AB Phone: +46 (0) 703 31 90 51

Elicera Therapeutics announces outcome in rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.   Elicera Therapeutics AB (publ) (“Elicera” or the “Company”) has completed the rights issue of units consisting of shares and warrants of series TO2 which the

BioStock: Elicera collaborates with US cancer centre to evaluate iTANK

Elicera Therapeutics is the sole biotech in Sweden developing CAR T-cell therapies. Beyond that, the company has developed a technology - the iTANK platform - with the potential to boost any T-cell receptor therapy – not just Elicera’s. This week, the company announced entering a Material Transfer Agreement with a prominent, still undisclosed, cancer centre based in the US to evaluate iTANK in a novel T-cell receptor therapy targeting skin cancer and lung cancer. BioStock caught up with Elicera’s CEO Jamal El-Mosleh to learn more.Read the interview with Jamal El-Mosleh at biostock.se:

Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Elicera Therapeutics AB (publ) ("Elicera" or the "Company") has received additional subscription commitments from members of the board and management in the ongoing

The subscription period in Elicera Therapeutics’ rights issue of units starts today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.   Today, February 23, 2024, the subscription period begins in Elicera Therapeutics AB’s (publ) (“Elicera” or the “Company”) rights issue of units consisting of

Elicera Therapeutics publishes prospectus in connection with rights issue of units

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Elicera Therapeutics AB (publ) ("Elicera" or the "Company") has prepared an EU growth prospectus (the "Prospectus") for the forthcoming issue of units consisting of

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media